van Leenders GJ - Search Results

1

Antibody EPR3864 is specific for ERG genomic fusions in prostate cancer: implications for pathological practice.

van Leenders GJ, Boormans JL, Vissers CJ, Hoogland AM, Bressers AA, Furusato B, Trapman J. van Leenders GJ, et al. Mod Pathol. 2011 Aug;24(8):1128-38. doi: 10.1038/modpathol.2011.65. Epub 2011 Apr 15. Mod Pathol. 2011. PMID: 21499236 Free article.

2

Histopathological changes associated with high intensity focused ultrasound (HIFU) treatment for localised adenocarcinoma of the prostate.

Van Leenders GJ, Beerlage HP, Ruijter ET, de la Rosette JJ, van de Kaa CA. Van Leenders GJ, et al. Among authors: van de kaa ca. J Clin Pathol. 2000 May;53(5):391-4. doi: 10.1136/jcp.53.5.391. J Clin Pathol. 2000. PMID: 10889823 Free PMC article.

3

Expression of basal cell keratins in human prostate cancer metastases and cell lines.

van Leenders GJ, Aalders TW, Hulsbergen-van de Kaa CA, Ruiter DJ, Schalken JA. van Leenders GJ, et al. J Pathol. 2001 Dec;195(5):563-70. doi: 10.1002/path.993. J Pathol. 2001. PMID: 11745692

4

Histopathological characteristics of lymph node metastases predict cancer-specific survival in node-positive prostate cancer.

Boormans JL, Wildhagen MF, Bangma CH, Verhagen PC, van Leenders GJ. Boormans JL, et al. Among authors: van leenders gj. BJU Int. 2008 Dec;102(11):1589-93. doi: 10.1111/j.1464-410X.2008.07904.x. Epub 2008 Aug 14. BJU Int. 2008. PMID: 18710447

5

An activating mutation in AKT1 in human prostate cancer.

Boormans JL, Hermans KG, van Leenders GJ, Trapman J, Verhagen PC. Boormans JL, et al. Among authors: van leenders gj. Int J Cancer. 2008 Dec 1;123(11):2725-6. doi: 10.1002/ijc.23787. Int J Cancer. 2008. PMID: 18798258 Free article. No abstract available.

6

False-negative prostate needle biopsies: frequency, histopathologic features, and follow-up.

Wolters T, van der Kwast TH, Vissers CJ, Bangma CH, Roobol M, Schröder FH, van Leenders GJ. Wolters T, et al. Among authors: van leenders gj, van der kwast th. Am J Surg Pathol. 2010 Jan;34(1):35-43. doi: 10.1097/PAS.0b013e3181c3ece9. Am J Surg Pathol. 2010. PMID: 19935058

7

E17K substitution in AKT1 in prostate cancer.

Boormans JL, Korsten H, Ziel-van der Made AC, van Leenders GJ, Verhagen PC, Trapman J. Boormans JL, et al. Among authors: van leenders gj. Br J Cancer. 2010 May 11;102(10):1491-4. doi: 10.1038/sj.bjc.6605673. Epub 2010 Apr 20. Br J Cancer. 2010. PMID: 20407443 Free PMC article.

8

No evidence of FGFR3 mutations in prostate cancer.

Zuiverloon TC, Boormans JL, Trapman J, van Leenders GJ, Zwarthoff EC. Zuiverloon TC, et al. Among authors: van leenders gj. Prostate. 2011 May;71(6):637-41. doi: 10.1002/pros.21279. Epub 2010 Oct 18. Prostate. 2011. PMID: 20957671

9

Cysteine-rich secretory protein 3 and β-microseminoprotein on prostate cancer needle biopsies do not have predictive value for subsequent prostatectomy outcome.

Hoogland AM, Dahlman A, Vissers KJ, Wolters T, Schröder FH, Roobol MJ, Bjartell AS, van Leenders GJ. Hoogland AM, et al. Among authors: van leenders gj. BJU Int. 2011 Oct;108(8):1356-62. doi: 10.1111/j.1464-410X.2010.10059.x. Epub 2011 Mar 16. BJU Int. 2011. PMID: 21410630

10

Diagnostic and prognostic signatures from the small non-coding RNA transcriptome in prostate cancer.

Martens-Uzunova ES, Jalava SE, Dits NF, van Leenders GJ, Møller S, Trapman J, Bangma CH, Litman T, Visakorpi T, Jenster G. Martens-Uzunova ES, et al. Among authors: van leenders gj. Oncogene. 2012 Feb 23;31(8):978-91. doi: 10.1038/onc.2011.304. Epub 2011 Jul 18. Oncogene. 2012. PMID: 21765474

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

236 results

Search Page